Journal rankings · indicator year 2023
Choose a field to open its ranking, or a journal to find its row in its subfield’s list.
Subfield ranking · 2023
Cancer Research journal rankings 2023
26 ranked journals · Subfield in Biochemistry, Genetics and Molecular Biology
Cancer Research has 26 ranked journals in 2023. The median OJR rose 0.09 on 2022 to 0.79, below the world average of 1.00; Q1 starts at OJR 1.02. The top three are Cancer & Metabolism, Mutation Research/Reviews in Mutation Research, and The Breast.
Ranks and citation indicators: 2023. Journal access status and listed APC: source snapshot September 23, 2026.
Journals whose main subfield sits in this category and that published at least 30 citable documents (articles, reviews and conference papers) in 2020–2022, the window the 2023 score is computed on.
The OpenJournalRank Indicator (OJR) is a free, publicly available metric of a journal’s field-normalized citation impact, computed from open OpenAlex citation data. It compares citations to a journal’s papers from the previous three years with the world average for papers of the same subfield, year and type, so 1.00 is the world average and values can be compared across fields. It is computed with the NCI3 method.
The middle OJR among ranked journals in this category: half score higher, half lower. 1.00 is the world average for papers of the same subfield, year and type.
The dot is this category, the solid tick is the median of all ranked journals and the dashed line is the world average.
Share of ranked journals in this category that are fully open access, so every paper is free to read. Hybrid journals, which sell subscriptions and open single papers for a fee, are not counted.
Median list price of the article processing charge, in US dollars, among ranked journals in this category that list a price above zero. Journals with a listed APC of $0 and journals with no known price are left out of this median. The At a glance table below gives a second median that includes the $0 prices.
Subfields of Biochemistry, Genetics and Molecular Biology (14)
26 ranked journals
Filters
Rank is the position by OJR within the list on screen; 1 is the highest. | OJR is field-normalized 3-year citation impact: 1.00 is the world average for papers of the same subfield, year and type, so values compare across fields. The badge is the journal’s quartile in this list. | Citations per paper over a two-year window, counted from OpenAlex. It is not field-normalized, so compare it only between journals of the same field. ▲ or ▼ is the change from 2022. This is OpenJournalRank’s own count, not Clarivate’s Journal Impact Factor. | Citable documents (articles, reviews and conference papers) published in 2020–2022, the window the 2023 OJR is computed on. A journal needs at least 30 to be ranked. | Share of the journal’s 2020–2022 papers that are free to read in any open-access form. The green OA tag next to a title marks a fully open-access journal. | List price of the article processing charge in US dollars. “$0 listed” means the listed price is zero; a dash means no price is listed. | The line is the journal’s OJR from 2014 to 2023. | Compare |
|---|---|---|---|---|---|---|---|
1Cancer & MetabolismOABioMed Central · United Kingdom | 1.79Q1 | 6.86 0.48 up from 2022 | 93 | 100% | $3,190 | ||
2Mutation Research/Reviews in Mutation ResearchElsevier BV · Netherlands | 1.56Q1 | 8.61 3.11 up from 2022 | 90 | 64% | $4,160 | ||
3The BreastOAElsevier BV · United Kingdom | 1.50Q1 | 6.66 2.72 up from 2022 | 489 | 100% | $3,200 | ||
4Biomarker InsightsOASAGE Publishing · United Kingdom | 1.35Q1 | 4.17 0.17 up from 2022 | 63 | 100% | $2,650 | ||
5Non-coding RNA ResearchOAElsevier BV · China | 1.30Q1 | 6.03 0.76 up from 2022 | 101 | 100% | $1,100 | ||
6Journal of Molecular DiagnosticsElsevier BV · United States | 1.10Q1 | 3.65 0.42 down from 2022 | 403 | 100% | $3,000 | ||
7Breast CancerSpringer Science+Business Media · Japan | 1.02Q1 | 3.58 0.56 down from 2022 | 360 | 54% | $3,890 | ||
8Non-Coding RNAOAMultidisciplinary Digital Publishing Institute · Switzerland | 0.99Q2 | 3.98 0.71 down from 2022 | 209 | 100% | $2,172 | ||
9Breast Cancer Research and TreatmentSpringer Science+Business Media · Netherlands | 0.97Q2 | 3.26 0.64 down from 2022 | 1,273 | 60% | $4,190 | ||
10BiomedicineOAEDP Sciences · Netherlands | 0.90Q2 | 2.93 0.97 up from 2022 | 89 | 100% | — | ||
11Clinical Breast CancerElsevier BV · United States | 0.89Q2 | 2.93 0.17 down from 2022 | 491 | 37% | $3,470 | ||
12Breast Cancer Basic and Clinical ResearchOASAGE Publishing · United States | 0.84Q2 | 2.49 0.61 down from 2022 | 84 | 100% | $2,650 | ||
13MutagenesisOxford University Press · United Kingdom | 0.81Q2 | 3.42 1.12 up from 2022 | 100 | 68% | $4,170 | ||
14Pathology - Research and PracticeElsevier BV · Germany | 0.77Q3 | 3.09 0.19 up from 2022 | 1,185 | 23% | $2,780 | ||
15Genes and EnvironmentOABioMed Central · Japan | 0.71Q3 | 3.04 0.79 up from 2022 | 111 | 100% | $2,590 | ||
16Mutation Research/Genetic Toxicology and Environmental MutagenesisElsevier BV · Netherlands | 0.69Q3 | 2.60 0.19 up from 2022 | 232 | 25% | $3,350 | ||
17British Journal of Biomedical ScienceOATaylor & Francis · United Kingdom | 0.64Q3 | 2.88 0.85 up from 2022 | 100 | 100% | $2,506 | ||
18Environmental and Molecular MutagenesisWiley · United States | 0.64Q3 | 2.41 0.26 down from 2022 | 131 | 73% | $3,750 | ||
19Journal of Breast CancerOASouth Korea | 0.63Q3 | 2.33 0.13 down from 2022 | 162 | 100% | $500 | ||
20Critical Reviews in Eukaryotic Gene ExpressionBegell House · United States | 0.51Q3 | 1.42 0.10 down from 2022 | 189 | 12% | — | ||
21Journal of Molecular PathologyOAMultidisciplinary Digital Publishing Institute · Switzerland | 0.51Q4 | 1.74 0.09 up from 2022 | 64 | 100% | $1,207 | ||
22The Breast JournalOAWiley · United Kingdom | 0.42Q4 | 1.59 0.36 up from 2022 | 494 | 100% | $2,350 | ||
23Breast DiseaseIOS Press · Netherlands | 0.39Q4 | 1.08 0.21 down from 2022 | 127 | 89% | — | ||
24MicroRNABentham Science Publishers · Netherlands | 0.29Q4 | 1.19 0.22 down from 2022 | 79 | 0% | — | ||
25Journal of Biomaterials and Tissue EngineeringAmerican Scientific Publishers · United States | 0.03Q4 | 0.10 0.01 down from 2022 | 862 | 1% | — | ||
26International Journal of Human GeneticsOAKamla Raj Enterprises · India | 0.01Q4 | 0.02 0.05 down from 2022 | 77 | 100% | — |
Subfields of Biochemistry, Genetics and Molecular Biology, with Cancer Research highlighted.
- Molecular Biology1,167
- Genetics120
- Cancer Research26
- Cell Biology26
- Molecular Medicine9
- Biophysics7
- Clinical Biochemistry4
- Biochemistry3
- Structural Biology2
- Developmental Biology1
- Physiology1
- Aging0
- Biotechnology0
- Endocrinology0
Journals
Citations made in 2023. Corpus-wide, 88.9% of core-journal articles and reviews published that year have at least one matched reference; the share varies by journal and field.
16 additional Cancer Research journals with metrics are unranked under this release’s eligibility rules: a journal needs at least 30 citable documents in 2020–2022, at least 80% of them with a subfield, and a positive world-average expectation. Ranks are within the whole category; filters hide rows without re-ranking. OJR excludes self-citations.
At a glance
Indicator year: 2023. Publication window: 2020–2022. How these summaries are calculated
- Ranked journals
- 26
- Window papers (baseline)
- 64,646 +12.3% from indicator year 2020
- Median OJR
- 0.79 +4.3% from indicator year 2020
- Rising journals (2025)
- 2
Window papers are the baseline paper population: citable papers (articles, reviews and conference papers) from 2020–2022 in all journals of the world-average baseline, including non-core journals, counted by each paper’s own subfield. They are not the papers of the ranked journals alone.
| Measure | Year series | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ranked journals | 12 | 14 | 15 | 16 | 16 | 19 | 20 | 21 | 21 | 22 | 21 | 20 | 21 | 24 | 23 | 25 | 26 | 27 | 28 | 27 | 29 | 27 | 27 | 26 | 27 | 29 | |
| Window papers (baseline) | 14,247 | 15,312 | 16,615 | 17,745 | 18,774 | 20,529 | 22,718 | 25,259 | 27,535 | 30,135 | 32,914 | 35,940 | 38,839 | 41,424 | 44,722 | 47,640 | 50,019 | 51,182 | 52,328 | 54,530 | 57,576 | 61,698 | 64,508 | 64,646 | 60,806 | 56,699 | |
| Median OJR | 0.49 | 0.50 | 0.46 | 0.60 | 0.71 | 0.58 | 0.67 | 0.680 | 0.768 | 0.8139 | 0.72 | 0.798 | 0.93 | 0.92 | 0.88 | 0.84 | 0.7969 | 0.8143 | 0.804 | 0.82 | 0.76 | 0.679 | 0.70 | 0.79 | 0.770 | 0.7966 |
How to read these rankings
- OJR, the OpenJournalRank Indicator
- A field-normalized 3-year citation impact, computed from OpenAlex with the NCI3 method. It divides the citations a journal’s papers received by the world average for papers of the same subfield, year and type, so 1.00 is the world average and 2.00 means twice as many citations as expected. Because it is normalized, it can be compared across fields. Read the methodology
- Quartiles
- Q1 to Q4 split the ranked journals of the list you are viewing into four equal groups by OJR. A journal’s quartile depends on the list: the same journal can be Q1 in its subfield and Q2 among all journals.
- Impact factor (2-year)
- Citations per paper over a two-year window, counted from OpenAlex. It is easy to compare with familiar impact factors but is not field-normalized, so compare it only within a field. It is not Clarivate’s Journal Impact Factor. Why it differs from the Journal Impact Factor
- Rank ranges
- Each rank in the latest year carries a likely range from 1,000 resamples of the journal’s papers. Where two journals’ ranges overlap, the data cannot tell them apart, so treat neighbouring ranks as ties.